443998-65-0

Basic information

• Product Name: 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE
• Synonyms: 4-(4-BROMO-PHENYLAMINO)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE;tert-butyl 4-(4-bromoanilino)piperidine-1-carboxylate;TERT-BUTYL 4-(4-BROMOPHENYLAMINO)-PIPERIDINE-1-CARBOXYLATE
• CAS NO: 443998-65-0
• Molecular Formula: C₁₆H₂₃BrN₂O₂
• Molecular Weight: 355.27
• Mol File: 443998-65-0.mol

Chemical Properties

• Boiling Point: 439.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.336±0.06 g/cm3(Predicted)
• PKA: 4.18±0.20(Predicted)
• CAS DataBase Reference: 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE(443998-65-0)
• EPA Substance Registry System: 1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE(443998-65-0)

Safety Data

• Hazardous Substances Data: 443998-65-0(Hazardous Substances Data)

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 862652-46-8 (4-bromo-phenyl)-piperidin-4-yl-amine 
• 862652-50-4 (4-bromo-phenyl)-(1-ethyl-piperidin-4-yl)-amine 
• 862652-52-6 (4-bromo-phenyl)-(1-cyclopropylmethyl-piperidin-4-yl)-amine 
• 862652-48-0 (4-bromo-phenyl)-(1-cyclopentyl-piperidin-4-yl)-amine 
• 501446-70-4 C₂₃H₂₉BrN₂O₂ 
• 501674-12-0 4-[N-(4-Bromophenyl)-N-[[3-(3,4,5-trimethoxyphenyl)pyridin-5-yl]methyl]amino]-1-(tert-butoxycarbonyl)piperidine 
• 501674-14-2 4-[N-(4-Bromophenyl)-N-[3-(3,4,5-trimethoxyphenyl)benzyl]amino]-1-(tert-butoxycarbonyl)piperidine 
• 947607-17-2 4-(4-pyrimidin-2-yl-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester 
• 501446-71-5 C₁₈H₂₁BrN₂ 
• 1350809-19-6 C₁₈H₂₀BrClN₂ 
• 1350809-20-9 C₁₈H₂₀BrClN₂ 
• 1350809-21-0 C₁₈H₂₀BrClN₂ 

Relevant articles and documents

TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, Q2, L1 and n are as defined herein. The compounds have antifungal properties and are useful in the treatment of fungal infections, including infections that are resistant to conventions anti-fungal agents. Q1 is selected from: (Formulae Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij and Ik) wherein * indicates the point of attachment to L1.

Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of α-glycoprotein were evaluated in rat and dog pharmacokinetics.

Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists

Structural features of the substituted 4-piperidinyl urea analogs 1, responsible for the H3 antagonist activity, have been identified. Structure-activity relationship of the H3 receptor affinity, hERG ion channel inhibitory activity and their separation is described. Preliminary pharmacokinetic evaluation of the compounds of the series is addressed.

ERYTHROPOIETIN PRODUCTION ACCELERATOR

The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein, ???R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; ???W1 and W2 each independently represent N or CH; ???X represents O, NR4, CONR4 or NR4CO; ???R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and ???l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

Biaryl ureas as potent and orally efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity

Herein, we report a small molecule MCH-R1 antagonist which demonstrates oral efficacy in chronic rodent models. Substituted phenyl biaryl urea derivatives were synthesized and evaluated as MCH-R1 antagonists for the treatment of obesity. The structure-activity relationship studies in this series resulted in identification of urea 1 as a potent and selective MCH-R1 antagonist. Compound 1 exhibited oral efficacy in chronic (28 d) rodent models at 3-30 mpk showing significant reduction in food intake and weight gain relative to controls.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group;W1 and W2 each independently represent N or CH;X represents O, NR4, CONR4 or NR4CO;R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; andl, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

Piperidine derivatives useful as CCR5 antagonists

The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined in the specification. The present invention also provides pharmaceutical compositions containing the compound of this invention, and methods of treatment using the compound of this invention. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group; W1 and W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.